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A major function of proteasomes and macroautophagy is to eliminate misfolded potentially toxic proteins.
Mammalian proteasomes, however, cannot cleave polyglutamine (polyQ) sequences and seem to release
polyQ-rich peptides. Puromycin-sensitive aminopeptidase (PSA) is the only cytosolic enzyme able to
digest polyQ sequences. We tested whether PSA can protect against accumulation of polyQ fragments. In
cultured cells, Drosophila and mouse muscles, PSA inhibition or knockdown increased aggregate content
and toxicity of polyQ-expanded huntingtin exon 1. Conversely, PSA overexpression decreased aggregate
content and toxicity. PSA inhibition also increased the levels of polyQ-expanded ataxin-3 as well as
mutant a-synuclein and superoxide dismutase 1. These protective effects result from an unexpected ability
of PSA to enhance macroautophagy. PSA overexpression increased, and PSA knockdown or inhibition
reduced microtubule-associated protein 1 light chain 3-II (LC3-II) levels and the amount of protein degra-
dation sensitive to inhibitors of lysosomal function and autophagy. Thus, by promoting autophagic protein
clearance, PSA helps protect against accumulation of aggregation-prone proteins and proteotoxicity.
INTRODUCTION
The accumulation of aggregate-prone proteins in neurons is a
hallmark of many neurodegenerative disorders, including the
polyglutamine tract expansion diseases such as Huntington’s
disease and spinocerebellar ataxia type 3, familial forms of
Parkinson’s disease and amyotrophic lateral sclerosis [caused
by point mutations in a-synuclein and superoxide dismutase
1 (SOD1), respectively]. These abnormal proteins are
thought to cause disease via toxic gain-of-function mechan-
isms. Thus, one rational approach to combating their toxicity
is to reduce the cellular content of the mutant protein by accel-
erating their degradation.
The two major routes for protein degradation within
mammalian cells are macroautophagy and the ubiquitin–
proteasome system. Degradation by the macroautophagy–
lysosomal pathway begins with the formation of double-
layered autophagosomes that enclose portions of cytoplasm.
These vacuoles ultimately fuse with lysosomes, and the cyto-
solic components are degraded by its various lysosomal acid
hydrolases. Macroautophagy (which we call here autophagy)
is a key mechanism for the clearance of many aggregation-
prone (or aggregated) proteins associated with neurodegenera-
tive diseases, including mutant forms of huntingtin, SOD1 and
a-synuclein (1). Furthermore, activation of this autophagic
process (e.g. by rapamycin) enhances the removal of the
aggregate-prone proteins such as mutant huntingtin and
attenuates its toxicity in cell and animal models (2). The ubi-
quitin–proteasome pathway also plays a critical role in the
selective degradation of misfolded, mutated or damaged
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series of enzymes that covalently attach a chain of ubiquitin
molecules onto lysine residues on the protein. This polyubi-
quitin chain serves as a recognition motif for binding of the
protein to the 26S proteasome. The ubiquitinated proteins
are digested to small peptides within the core 20S proteasome
particle. This barrel-shaped particle contains three types of
peptidase sites that can cleave nearly all peptide bonds in pro-
teins. The short (2–20) residue peptides typically released by
the proteasome are then rapidly hydrolyzed to amino acids by
cytosolic endo- and aminopeptidases.
The ubiquitin–proteasome pathway can efﬁciently digest
soluble misfolded proteins, but once proteins such as hunting-
tin are aggregated, the autophagic/lysosomal process assumes
primary importance in their clearance from the cytosol (3–5).
However, in the case of proteins containing polyglutamine
tracts, eukaryotic proteasomes can cleave only very poorly
(if at all) within polyglutamine sequences (6). Consequently,
in degrading huntingtin, the 26S proteasome appears to
release polyglutamine-rich fragments for digestion by cytoso-
lic peptidases (6,7). Because they lack extensive ﬂanking
sequences, such peptides have a very strong tendency to
aggregate (probably even stronger than that of the full-length
protein). Therefore, the rapid hydrolysis of these
polyglutamine-rich peptides seems likely to be important in
preventing or retarding the progression of polyglutamine dis-
orders. Most larger peptides released by proteasomes are
initially digested by endopeptidases (8–10), and the resulting
shorter peptides are rapidly hydrolyzed to amino acids by
various cytosolic aminopeptidases (11–14).
Surprisingly, only one cytosolic peptidase, puromycin-
sensitive aminopeptidase (PSA, also termed cytosol alanyl
aminopeptidase, human gene symbol NPEPPS), was found
to be able to digest short polyglutamine peptides (15). PSA
is a ubiquitous, 100 kDa, Zn
2+ metallopeptidase present in
high concentrations in the brain (especially in the striatum,
the hippocampus and the cerebellum) (16,17). Although PSA
was initially described as an enkephalin-degrading enzyme
(18,19), its localization predominantly in the cytoplasm and
its broad distribution in tissues argue against such a function.
Instead, a role for PSA in digesting proteasome products to
amino acids or antigenic peptides presented on MHC Class I
molecules seems most likely based on its cytosolic location
and its ability to digest diverse sequences (12–14,20). In
fact, we have found that PSA is the dominant intracellular pep-
tidase in degrading a large variety of dipeptides (R.H. and
A.L.G., unpublished data).
These observations suggest that a loss of PSA function
could lead to a toxic accumulation of fragments of normal
gene products and increase the susceptibility to polyglutamine
diseases. In fact, PSA-deﬁcient mice display behavioural and
neurological abnormalities (17,21) including movement dis-
orders that perhaps are related to the failure to rapidly clear
peptides released by the proteasomes which could have dele-
terious effects. Interestingly, the expression of PSA was
found to be highly induced in PC12 cells upon expression of
huntingtin exon 1 containing an expanded, but not a normal
length, polyQ sequence (22). In addition, PSA is induced in
the CNS in a mouse model of fronto-temporal dementia
expressing a mutated tau (16). Furthermore, overexpression
of PSA had a remarkable ability to protect against neurodegen-
eration induced by misexpression of the longest isoform of
human tau in Drosophila (16).
The present studies were undertaken to test whether PSA
may play an important role in the clearance of polyQ-rich
fragments, polyQ-containing proteins or other mutant poly-
peptides associated with neurodegenerative diseases. We
have tested whether altering the activity or content of PSA
modiﬁes aggregate accumulation and toxicity of different
forms of mutant huntingtin exon 1 in cell culture and in vivo
models of neurodegenerative diseases. Using a variety of
approaches and experimental systems, we show that PSA is
an important determinant of aggregate content and of hunting-
tin exon 1 toxicity. Surprisingly, this ability of PSA to reduce
the content of aggregates formed by huntingtin exon 1, as well
as another expanded polyQ protein, ataxin-3, correlated with
an ability of PSA to promote autophagy. Indeed, PSA was
found to enhance the clearance of a range of aggregation-
prone proteins associated with neurodegenerative diseases,
including some proteins lacking polyglutamine expansions,
and to increase intracellular protein degradation by promoting
autophagy. These studies have uncovered a surprising new
function of this cytosolic peptidase in regulating autophagy
and a remarkable ability of PSA activity to inﬂuence aggregate
content and toxicity in a variety of neurodegenerative diseases.
RESULTS
Decrease in PSA activity increases the aggregation
and toxicity of expanded huntingtin exon 1
To test whether PSA activity might affect the cellular content
of polyglutamine aggregates and toxicity, we studied the
effects of knocking down PSA expression using RNA interfer-
ence (RNAi) (Supplementary Material, Fig. S1A) and of
pharmacological inhibitors of PSA activity in HeLa,
HEK293A and HEK293T cells. Depletion of this enzyme in
HeLa cells expressing mutant huntingtin with 74 polygluta-
mine repeats (Q74) exon 1 fused to GFP increased the percen-
tage of cells that displayed macroaggregates as well as the
number of apoptotic nuclei (Fig. 1A). Similarly, PSA knock-
down in cells expressing a huntingtin–GFP construct with
103 glutamines enhanced the percentage of cells with aggre-
gates (Supplementary Material, Fig. S1B). This result was cor-
roborated when levels of insoluble macroaggregates in whole
cell lysates were measured using the ﬁlter trap assay (Fig. 1B).
Surprisingly, even though cells expressing the non-expanded
Q23 huntingtin exon 1 GFP do not normally contain visible
aggregates, decreasing PSA expression also led to the appear-
ance of intracellular accumulations, similar to the inclusions
we observed with expanded huntingtin exon 1; however,
these may not necessarily have the same structure as the
expanded polyQ aggregates. This was accompanied by an
increase in the frequency of apoptotic nuclei (Fig. 1C).
Thus, PSA appears to play a role in clearance of both
expanded and normal length huntingtin exon 1.
In order to determine whether this effect of PSA on
formation of aggregates is due to its enzymatic activity, we
employed the general aminopeptidase inhibitor, bestatin, and
the speciﬁc PSA inhibitor, PAQ-22. In 293A cell extracts,
4574 Human Molecular Genetics, 2010, Vol. 19, No. 23Figure 1. PSA knockdown and inhibition increase aggregation and toxicity in cells expressing normal and polyglutamine-expanded huntingtin exon 1. (A) HeLa
cells were treated with PSA siRNA and then transfected with plasmids encoding exon 1 of huntingtin with polyglutamine tract length of 74, tagged with EGFP
(htt-exon-1-GFP). The proportion of transfected (GFP-positive) cells containing GFP aggregates was measured (black bars) and cellular toxicity was assessed by
measuring the proportion of transfected cells with apoptotic nuclei, visualized by DAPI staining (grey bars). Aggregation and toxicity were increased by the
knockdown of PSA. Data shown are normalized to control levels of aggregation and cell death and combined from four independent experiments, each performed
in triplicate. Error bars represent SEM, as for all graphs in this study. In control conditions, the proportion of cells with GFP-positive macroaggregates and
apoptotic nuclei were typically 6 and 4%, respectively. ∗∗∗P , 0.001, ∗P , 0.05 by odds ratio. (B) Aggregation was also measured by ﬁlter trap assay in
HEK 293T cells using htt-exon-1-Q103-GFP. Lysates from cells treated with PSA siRNA contained more insoluble aggregates trapped on the ﬁlter membrane
as shown by the increase in GFP staining. (C) Effect of PSA knockdown on aggregation of htt-exon-1-GFP with a polyglutamine repeat length of 23 was
measured, exactly as in (A); data are shown normalized to control. The proportions of control cells with macroaggregates and apoptotic nuclei were 2 and
1%, respectively. ∗∗∗P , 0.001 (D–F). Small molecular inhibitors of PSA also increased aggregation of polyglutamine proteins with a range of repeat
lengths. 293A cells were transfected with htt-exon-1-GFP with 23Q (D), 41Q (E) or 74Q (F). PSA was inhibited with PAQ-22 (dark grey lines) or bestatin
(light grey lines) to either 50 or 80% of its endogenous activity: 50% inhibition: 0.05 mM bestatin, 0.12 mM PAQ-22; 80% inhibition: 0.5 mM bestatin, 1 mM
PAQ-22. The number of transfected cells containing GFP-positive aggregates was counted at the time points indicated. ∗∗∗P , 0.001, ∗P , 0.05 by
two-way ANOVA followed by post hoc Fisher’s LSD test. (G) In intact WT MEF cells, 80% of Ala-amc cleavage was inhibited by minimal effective concen-
tration of both PAQ (10 mM) and bestatin (5 mM). In PSA2/2 MEF cells, PAQ and bestatin inhibit only 10 and 20% of the residual Ala-amc cleavage activity,
which must be by other aminopeptidases. ∗∗P ¼ 0.001. (H) Bestatin (0.5 mM) treatment increased aggregation of HA-tagged huntingtin exon 1 with 74Q in HeLa
cells, but not following knockdown of PSA by siRNA. ∗P , 0.05, ns, not signiﬁcant by odds ratio.
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aminopeptidase activity [assayed ﬂuorometrically with the
alanine amino methylcoumarin (Ala-amc) substrate] with
IC50s of 0.07 and 0.08 mM, respectively (Supplementary
Material, Fig. S1C). By measuring the potency of these inhibi-
tors of PSA in intact 293A cells (Supplementary Material, Fig.
S1D) at concentrations where these drugs do not alter cellular
viability for several days (Supplementary Material, Fig. S1E),
we were able to assess how the level of PSA activity inﬂu-
ences aggregate content in 293A cells expressing huntingtin
exon 1 GFP with either 23 [wild-type (WT)], 41 or 74 gluta-
mines (Fig. 1D–F and Supplementary Material, Fig. S1F).
PSA inhibition increased aggregate content 2–4-fold not only
with expanded polyQ, where aggregates are more abundant
(Q74 and Q41), but also with the WT (23Q) huntingtin exon 1
GFP. In fact, the relative stimulation appeared larger with the
23Q construct, perhaps because the appearance of inclusions is
easier to detect with this construct, since it fails to aggregate sig-
niﬁcantlyundernormalcircumstances.Itisnoteworthythatlarge
increases in aggregate content were seen with only a 50%
decrease in enzyme activity using either inhibitor.
We conﬁrmed the relative speciﬁcity of these inhibitors by
comparing their activities in mouse embryonic ﬁbroblasts
(MEFs) from WT and PSA-null mice. In intact cells, the clea-
vage of Ala-amc was ﬁve times higher in WT MEFs than in
MEFs from PSA knockout mice. In WT MEFs, 80% of the
Ala-amc cleavage was sensitive to both PAQ (10 mM) and bes-
tatin (5 mM), whereas PAQ and bestatin had negligible effects
on its hydrolysis in the PSA knockout MEFs (Fig. 1G). Further
evidence that bestatin increased aggregate number through
PSA inhibition was the ﬁnding that, following RNAi knock-
down of PSA, this inhibitor had no effect in cells expressing
huntingtin exon 1 Q74 GFP (Fig. 1H). Together, these ﬁndings
indicate that PSA is involved in the clearance of both
normal and polyQ-expanded huntingtin exon 1 and reducing
its activity by 50% increases huntingtin accumulation and
toxicity.
PSA overexpression reduces aggregates and toxicity
of mutant huntingtin exon 1
Consistent with the deleterious effects of PSA knockdown and
inhibition, we found that PSA overexpression (Supplementary
Material, Fig. S2A) decreased the frequency of expanded hun-
tingtin exon 1 GFP aggregates and the associated cell death in
neuroblastoma cells (Fig. 2A). Furthermore, in HeLa cells,
PSA overexpression not only reduced the fraction of cells
with inclusions, it also reduced the cells’ content of insoluble
huntingtin exon 1 GFP and the sizes of the inclusions
(Fig. 2B and Supplementary Material, Fig. S2B and C).
Because of the inability of the proteasome to cleave efﬁciently
within polyQ sequences, polyQ-rich peptides are likely to be
generated and released during the degradation of polyQ pro-
teins (6). In an attempt to mimic these isolated polyQ
sequences in the absence of a linked protein such as hunting-
tin, we expressed a GFP–ubiquitin–polyQ fusion protein (23).
In cells, the GFP–ubiquitin and the C-terminal polyQ
sequence are efﬁciently cleaved by deubiquitinating
enzymes, releasing pure polyQ polypeptide (Fig. 2C). When
293T cells were transfected with GFP–ubiquitin–polyQ
containing 65 or 112 glutamines, with or without PSA–GFP,
PSA overexpression reduced the levels of both the soluble
polyQ polypeptides and insoluble polyQ aggregates (assayed
by ﬁlter trap) (Fig. 2D and Supplementary Material,
Fig. S2D and E), in accord with our ﬁndings on expanded hun-
tingtin exon 1 (Fig. 2A and B and Supplementary Material,
Fig. S2B and C). However, it was not possible to assess
whether raising PSA levels had similar protective effects in
cells expressing WT huntingtin exon 1 GFP due to their
very low frequency of aggregates and cell death.
PSA suppresses accumulation of mutant huntingtin
aggregates and toxicity in vivo
To test whether overexpression of PSA causes a similar sup-
pression of huntingtin aggregates in mouse tissues in vivo,
we electroporated GFP-tagged huntingtin exon 1 constructs
bearing different polyQ lengths into the tibialis anterior
muscles of adult mice. One week after electroporation, the
huntingtin Q23 GFP was diffusely distributed in the electropo-
rated ﬁbres. However, transfection with expanded huntingtin
with 41 and 74Q caused the formation of GFP-labelled
inclusions in all the electroporated ﬁbres (Fig. 3A). When a
PSA-encoding plasmid was simultaneously electroporated, it
decreased the number and size of inclusions formed by the
expanded huntingtin exon 1 mCherry (74Q) in the tibialis
anterior muscle 1 week after electroporation (Fig. 3B). On
the other hand, transfecting a PSA RNAi construct enhanced
the formation of mutant huntingtin exon 1 mCherry aggregates
(Fig. 3C). Furthermore, when huntingtin exon 1 GFP with 74Q
or 41Q was electroporated in heterozygous PSA knockout
mice, more inclusions were evident than in WT mice
(Fig. 3D–E). The inclusions formed by huntingtin exon 1
(41Q) were larger in muscle of heterozygous PSA knockout
mice (Fig. 3E). Extracts of muscles from the heterozygous
mice showed an approximately 50% reduction in PSA activity
(data not shown). Thus, a decrease of only 50% in the
endogenous PSA activity is sufﬁcient to signiﬁcantly
enhance mutant huntingtin aggregate formation, as was also
found upon treatment of 293A cells with PSA inhibitors.
In order to test the effects of PSA on huntingtin toxicity in
neurons in vivo, we used two distinct Drosophila models with
different quantiﬁable readouts. In the ﬁrst, mutant huntingtin
exon 1 was expressed in the nervous system (24) and
reduced lifespan. In these ﬂies, PSA knockdown (with two
different RNAi constructs) further shortened the lifespan,
whereas PSA overexpression increased their lifespan
(Fig. 4A). In the second model, mutant huntingtin was
expressed in the photoreceptors. Fly photoreceptors that
express a mutant huntingtin fragment with 120 polyglutamine
repeats exhibit degeneration that is not observed in ﬂies that
express the WT fragment with 23 polyglutamine repeats
(25). The compound eye of Drosophila consists of about
800 ommatidia, each composed of eight photoreceptor
neurons with light-gathering parts called rhabdomeres, seven
of which can be visualized by light microscopy using the pseu-
dopupil technique (26). Neurodegeneration in these HD ﬂies is
progressive and associated with a decrease over time in the
number of visible rhabdomeres in each ommatidium (25).
However, PSA overexpression increased the number of
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of polyglutamine toxicity. On the other hand, the expression of
either of two different PSA RNAi constructs enhanced toxicity
(Fig. 4C and E). Thus, as in cell culture, modulation of PSA
levels alters polyQ toxicity in vivo.
PSA decreases aggregate number in cellular models
of other neurodegenerative diseases
To investigate whether PSA can also promote the clearance of
other aggregation-prone mutant proteins, we tested its effects
on different neurodegenerative disease-associated proteins
including ataxin-3, another polyglutamine-containing protein,
whose expansion causes spinocerebellar ataxia type 3. In
293A cells expressing WT (28Q) and mutant (84Q) full-length
ataxin-3 GFP, inhibition of PSA caused the accumulation of
more aggregates than in untreated control cells (Fig. 5A and
B and Supplementary Material, Fig. S4A). We also studied
aggregate-prone proteins that lack polyglutamine repeat
regions. In cells expressing a mutant form of SOD1, which
causes an inherited form of amyotrophic lateral sclerosis, the
number of SOD1 GFP inclusions was increased when PSA
was inhibited (Fig. 5C, D and Supplementary Material, Fig.
S4B). Furthermore, using PC12 cells, we were able to investi-
gate the clearance of A53T mutant a-synuclein, which causes
a familial form of Parkinson’s disease. Its levels can be accu-
rately measured by western blotting of the soluble fraction
because this protein does not aggregate in these cells. To
follow its degradation, a-synuclein expression was induced
by the addition of doxycycline to the media, and then switched
off by removal of the antibiotic. The degradation of A53T
a-synuclein was slowed (i.e. its level was higher 16 h after
synthesis was terminated) in the cells treated with the PSA
inhibitors (Fig. 5E and F). Thus, this enzyme promotes the
clearance and thus reduces aggregate content in a wide
variety of cellular models of neurodegenerative disease.
Figure 2. PSA overexpression reduces toxicity and aggregate content in cells expressing expanded polyQ huntingtin exon 1 and expanded polyglutamine tracts.
(A) Effect of PSA overexpression on aggregate content in SK-N-SH cells expressing htt-exon-1-Q74-GFP. The proportions of cells with GFP-positive macro-
aggregates and apoptotic nuclei were decreased by the overexpression of PSA, when assayed as in Figure 1A and C. Data shown are normalized to control for
each experiment and the average of data from four independent experiments carried out in triplicate are shown. In control conditions, typically around 30% of
transfected cells contained macroaggregates and 10% had apoptotic nuclei. ∗∗∗P , 0.001 by odds ratio. (B) Overexpression of PSA in 293T cells also decreased
levels of insoluble aggregates of htt-exon-1-Q103-GFP, as measured by ﬁlter-trap assay. Q103 aggregates were visualized using anti-GFP antibody. (C)T o
mimic the polyQ sequences that may be released by the proteasome, we used a GFP–ubiquitin–polyQ construct (23). Upon expression, the GFP–UB and
the polyQ peptide are efﬁciently cleaved by deubiquitinating enzyme(s), leading to the release of a polyQ polypeptide. (D) Levels of soluble and insoluble poly-
glutamine peptides were also decreased by overexpression of PSA in HEK293T cells transfected with GFP–UB–polyQ containing 65 or 112 glutamines. Levels
of both soluble polyQ peptides (upper panel, arrows mark monomeric polyQ peptides and arrowheads mark high molecular weight oligomeric structures) and
insoluble aggregates (lower panel) detected by an anti-polyglutamine antibody decreased, when PSA-GFP was co-transfected. Actin levels are shown as a
loading control.
Human Molecular Genetics, 2010, Vol. 19, No. 23 4577Figure 3. Effect of PSA overexpression and knockdown on the formation of polyglutamine aggregates in mouse muscle. (A) Cross-sections of mouse tibialis
anterior muscle electroporated with GFP or huntingtin exon 1 with 23, 41, 74Q fused to GFP (Htt23Q, Htt41Q, Ht74Q). One week after electroporation, the
formation of inclusions was observed in all ﬁbres electroporated with Htt41Q and Htt74Q. Fibres electroporated with GFP or Htt23Q showed a diffuse ﬂuor-
escence and no inclusions. Scale bar represents 100 mM.( B) PSA overexpression decreased the number and size of polyglutamine inclusions found in tibialis
anterior muscle 1 week after electroporation with expanded huntingtin exon 1 (74Q) and PSA. Note that Htt74Q is seen as red (fused to mCherry) in these
images. Graph shows inclusion number and size in ﬁbres where PSA (blue bars) or GFP (green bars) is overexpressed. (C–E) Reduction in the expression
of PSA by electroporation of RNAi increased the number and size of polyglutamine inclusions in mouse skeletal muscle electroporated with expanded huntingtin
exon 1. (C) Tibialis anterior muscle 1 week after electroporation with Htt74Q and a plasmid expressing either a scrambled RNAi, or an RNAi targeting PSA.
Reduction of PSA expression by RNAi increased the number and size of polyglutamine inclusions formed by expanded huntingtin exon 1 (74Q). (D) Electro-
poration of expanded huntingtin exon 1 (74Q) to tibialis anterior muscles of PSA+/2 heterozygous mice led to more inclusions than in muscle from WT
(PSA+/+) mice, 1 week after electroporation. These inclusions also seemed larger in PSA+/2 mice, but this effect did not reach statistical signiﬁcance
(P ¼ 0.09). (E) Electroporation of expanded huntingtin exon 1 (41Q) in PSA+/2 heterozygous mice led the formation of more, larger inclusions than in
muscle from WT (PSA+/+) mice 1 week after electroporation. Scale bar (B–E) represents 50 mM. ∗P , 0.05 by t-test.
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Many of the proteins found here to accumulate on PSA inhi-
bition or to be cleared faster upon PSA overexpression are
autophagy substrates, including mutant huntingtin exon 1, full-
length ataxin-3, mutant SOD1 and A53T a-synuclein (27,28).
In fact, a large fraction of long-lived cellular proteins, the bulk
of cell constituents, are degraded by this process (29). We
therefore tested whether changes in PSA activity inﬂuence
the overall rate of degradation of long-lived proteins.
In order to determine the rates of proteolysis by autophagy,
lysosomes and proteasomes, we measured protein degradation
rates in the presence or absence of speciﬁc inhibitors of the
proteasome (bortezomib/velcade), lysosomal acidiﬁcation
(chloroquine) or autophagy [3-methyladenine (3MA)], as we
previously described (29). Upon deprivation for serum and
Figure 4. Effect of PSA overexpression and knockdown in Drosophila.( A) PSA expression levels alter lifespan in ﬂies expressing htt-exon1 with 93 polyglu-
tamine repeats in the brain. Knockdown of PSA expression levels by expression of two different PSA RNAi constructs enhanced toxicity (elav-Gal4 Q93
PSA-RNAi1 and elav-Gal4 Q93 PSA-RNAi2), compared with ﬂies expressing mutant huntingtin alone (elav-Gal4 Q93). Overexpression of PSA (elav-Gal4
Q93 PSA) extended lifespan relative to ﬂies expressing Q93 alone. Graph shows Kaplan–Meier survival curves, P , 0.0001 in both cases. Expression of
PSA RNAi or PSA in ﬂies expressing WT huntingtin (elav-Gal4 Q20) did not affect lifespan (Supplementary Material, Fig. S3). (B–E) Degeneration was
also decreased by overexpression of PSA. Overexpression of PSA in the WT ﬂy eye using the glass promoter (gl-PSA) caused a slight decrease in rhabdomere
number compared with ﬂies expressing Q23 alone. However, when co-expressed with GMR-Q120, PSA protected against the neurodegeneration seen in these
ﬂies (B). (C) Expression of PSA RNAi enhanced neurodegeneration in ﬂies expressing GMR-Q120, using two RNAi lines (elav-Gal4 GMR-Q120 PSA-RNAi1
and elav-Gal4 GMR-Q120 PSA-RNAi2). Expression of PSA RNAi in ﬂies expressing Q23 did not affect rhabdomere number (Supplementary Material, Fig. S3),
∗P , 0.02, 2 tailed t-test. (D) Examples of rhabdomeres in ﬂies expressing GMR-Q120 with or without PSA (gl-PSA). (E) Examples of rhabdomeres in ﬂies
expressing mutant huntingtin GMR-Q120 when PSA is downregulated using two RNAi lines (PSA-RNAi1 and PSA-RNAi2).
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increased the total rate of protein degradation by enhancing
the rate of lysosomal and autophagy-dependent proteolysis
but did not affect the proteasomal process (Fig. 6A).
However, PSA had no measurable effect on any of these pro-
cesses in complete medium (Supplementary Material, Fig.
S5A–C) where autophagy makes only a minor contribution
to the degradation of long-lived proteins (Supplementary
Material, Fig. S5D).
On the other hand, knockdown of PSA expression using
RNAi (Fig. 6B) or treatment with inhibitors of its activity
(Fig. 6C) decreased the total and lysosomal proteolysis
measured after nutrient deprivation, but not proteasomal
degradation. Again, no signiﬁcant effect of PSA was seen in
complete medium (Supplementary Material, Fig. S5B and
C). Thus, the activity of this cytosolic enzyme, PSA, appears
to regulate the capacity of the autophagic–lysosomal
pathway to degrade normal cell proteins.
In order to test whether this alteration of autophagic
activity by PSA was a major contributor to the effects on
protein clearance seen following PSA knockdown or overex-
pression, we used 3MA to inhibit autophagy (30). The
decrease in aggregate content upon PSA overexpression
(Fig. 6D) and the increase following by PSA inhibition
(Fig. 6E) were both markedly attenuated by 3MA. These
ﬁndings further suggest that most of PSA’s ability to
protect against expanded huntingtin exon 1 inclusions was
via its ability to promote autophagy.
In order to directly assess the effects of PSA on the autop-
hagy pathway, we measured the steady-state levels of autopha-
gosomes using the microtubule-associated protein 1 light
chain 3 (LC3). All of these experiments were performed in
complete medium, to assess whether PSA could modulate
basal autophagy levels. During autophagic vacuole formation,
LC3 is modiﬁed post-translationally to form LC3-I, and then
converted to LC3-II, which associates with autophagosome
membranes. LC3-II levels, which thus reﬂect autophagosome
number when assayed relative to the loading control, actin,
were decreased by PSA inhibitors (Fig. 6F and G) and also
by transfection with PSA RNAi (Fig. 6H and I). Since
decreased LC3-II content could result from either impaired
synthesis or enhanced degradation after lysosomal fusion,
we assessed LC3-II synthesis by blocking its degradation
with the lysosomal proton pump inhibitor Baﬁlomycin A1.
As expected, this agent increased LC3-II levels in all con-
ditions (Fig. 6H and I), but after Baﬁlomycin A1 treatment,
the levels of LC3-II were lower in cells expressing PSA
siRNA (Fig. 6H and I) than in control cells (Fig. 6J and K).
Conversely, in PSA-overexpressing cells, LC3-II levels were
increased over control levels. These ﬁndings imply that PSA
promotes autophagy and clearance of the misfolded proteins
by enhancing autophagosome formation.
Figure 5. PSA inhibition enhances aggregate formation in cells expressing other aggregate-prone proteins (ataxin-3, mutant SOD1, mutant a-synuclein). (A and
B) PSA inhibition increased aggregate formation in 293A cells expressing full-length ataxin-3 GFP with 28Q (A) and 84Q (B). The proportion of transfected
cells with macroaggregates was also increased by inhibition of PSA in cells transfected with mutant SOD1 GFP G37R (C) or G93A (D). ∗∗∗P , 0.001, ∗∗P ,
0.01, ∗P , 0.05 by t-test. (E and F) Clearance of mutant a-synuclein (A53T) was slowed by inhibition of PSA. Stable inducible PC12 cells were treated with
doxycycline to induce expression of mutant a-synuclein, and subsequently expression was turned off by removal of doxycycline from the medium. When PSA
inhibitors were added after transgene expression was switched off, more a-synuclein remained present, indicating a decreased clearance. Levels of a-synuclein
remaining after 16 h were assayed by western blot, a representative image is shown in (E). Densitometric quantiﬁcation of this triplicate experiment is shown in
(F). ∗∗P , 0.01, ∗P , 0.05, by ANOVA.
4580 Human Molecular Genetics, 2010, Vol. 19, No. 23Figure 6. PSA activity enhances protein degradation by the autophagic/lysosomal pathway. (A–C) Effect of PSA modulation on different proteolytic pathways.
Degradation of long-lived protein was measured in 293A cells. Proteolysis rates were measured in the presence of inhibitors of proteasomes, lysosomes or autop-
hagy to determine ﬂux through each of these pathways in cells starved of serum and amino acids. Proteasomes, lysosomes and autophagy inhibitors were velcade/
bortezomib 1 mM, chloroquine 50 mM and 3-MA 10 mM, respectively. (A) PSA overexpression increased total, lysosomal and autophagy-dependent proteolysis.
(B) PSA knockdown by RNAi decreased total and lysosomal proteolysis. (C) PSA inhibitors reduced total and lysosomal proteolysis. ∗∗∗P , 0.0001. (D) Inhibit-
ing autophagy in SK-N-SH cells expressing Q74 huntingtin exon-1 GFP using 3-MA, reduced the protective effect of PSA overexpression on aggregate content.
Co-expression of PSA with htt-exon-1-GFP-74Q reduced the percentage of transfected cells with aggregates (grey bars). However, in the presence of 3-MA,
added immediately after transfection, the reduction in aggregation caused by PSA expression was decreased (black bars). Control values with and without
3-MA are set to 100% in each case to allow ease of comparison, although Q74 aggregation was higher in the presence of 3-MA. Actual mean values were
24% of cells having aggregates in control and 30% in 3-MA treated cells. (E) Inhibitors of PSA caused an increase in the proportion of cells expressing
htt-exon-1-GFP-Q74 with aggregates (grey bars), but if 3-MA was added at the same time as these inhibitors they did not increase the aggregate content
(black bars). Actual mean values for aggregation were 19% in control cells and 32% in 3-MA treated cells. ∗∗P , 0.01, ∗∗∗P , 0.001, ns, not signiﬁcant,
by odds ratio, relative to control. (F–K) Effect of PSA modulation on LC3-II levels. (F) Treatment of PC12 cells with PSA inhibitors also resulted in a decrease
in LC3-II levels, a marker for autophagosomes. The western blot shown is a representative data set, with actin shown as a loading control. Quantiﬁcation of data
obtained in triplicate samples is shown in (G). (H and I) In HeLa cells treated with PSA siRNA, LC3-II levels were decreased, whereas cells overexpressing PSA
showed increased levels of LC3-II (J and K). (I) and (K) show densitometric quantiﬁcation of data from four experiments carried out in triplicate. LC3-II level
changes were seen in the presence (grey bars) and absence (black bars) of baﬁlomycin A1, a lysosomal proton pump inhibitor. LC3-II levels are shown relative to
actin, as a loading control in each case. Values are normalized to control, in the presence or absence of baﬁlomycin, to allow for comparison between different
gels, although the levels of LC3-II were higher with baﬁlomycin than without. ∗P , 0.05, ∗∗P , 0.01.
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The protection conferred by PSA against polyQ and other
aggregation-prone proteins was observed here in a very wide
range of types of cells in culture, as well as in Drosophila
and mouse models of neurodegenerative diseases. In all
cases examined, cellular protection against these toxic proteins
coincided with decreased content of large inclusions contain-
ing the mutant polypeptide. However, this correlation does
not imply that the large aggregates are in fact the toxic
species, since aggregate formation and cytotoxicity probably
both depend on levels of misfolded proteins or microaggre-
gated species whose clearance is accelerated by PSA. In
addition to using various standard approaches to evaluate
aggregate formation and cell protection, we have introduced
a novel in vivo method—electroporation of a mutant gene
into muscle ﬁbre in adult mouse—that offers several major
advantages for such studies (e.g. rapid development of
inclusions, ability to use host animals of different genotypes
without lengthy mating, comparisons with control cells in
the same animals). Moreover, with this approach, increasing
the length of the polyQ tract of huntingtin exon 1 yielded
more inclusions, as observed in cell culture. In mouse
muscle ﬁbres, PSA knockdown increased while PSA overex-
pression reduced the content of inclusions formed by
expanded huntingtin exon 1, as we found in cell culture. Sur-
prisingly, in contrast to these marked results (obtained in three
labs), an earlier study had concluded that PSA does not inﬂu-
ence toxicity of mutant huntingtin in Drosophila (16), but that
study assessed polyglutamine toxicity by inspection of exter-
nal eye morphology, a rather insensitive qualitative approach,
in contrast to the quantitative analysis of the number of rhab-
domeres used here (Fig. 4).
The activation of autophagy by PSA
The ability of PSA to decrease aggregate content was not
restricted to cells expressing expanded huntingtin exon 1,
but was also observed with unattached long polyQ peptides,
full-length ataxin-3, mutant SOD1 and mutant a-synuclein.
This capacity of PSA to reduce the toxicity and accumulation
of aggregates containing expanded huntingtin exon 1 and these
other disease-associated proteins can be largely attributed to a
surprising new function of PSA: its ability to promote protein
degradation by autophagy. The enhancement of autophagy by
PSA constitutes a novel mechanism that seems to account for
the protective effects of PSA against this wide range of
aggregation-prone proteins. Since LC3-II levels and the
amount of protein degradation that is sensitive to 3MA or
chloroquine were increased by PSA overexpression and
reduced by PSA knockdown or inhibition, this enzyme
somehow must promote autophagosome formation. PSA was
previously shown to decrease the toxicity in Drosophila of
WT and mutant form of tau, which is associated with fronto-
temporal dementia (16). These effects were attributed to direct
degradation of tau by the aminopeptidase activity of PSA (31);
however, such an exoproteolytic mechanism would be quite
slow and inefﬁcient for digesting a protein as long as tau
and would generate heterogenous variants of tau of diverse
lengths. Since tau has been demonstrated to be an autophagy
substrate (27), it seems more likely that the enhancement of
autophagy by PSA might better explain the stimulation of
degradation of tau and the reduction in its toxicity upon
PSA overexpression. Interestingly, the two different PSA-
deﬁcient mouse lines are both characterized by abnormal
motor behaviour (17,21), which might also be a consequence
of reduced autophagy, since the blockage of this process in
Atg7-deﬁcient mice leads to major behavioural deﬁcits and
widespread inclusion bodies (32). On the other hand, upregu-
lation of autophagy via either mTOR-dependent or mTOR-
independent pathways protects cells from several
pro-apoptotic insults (33,34). Therefore, it seems likely that
PSA protects primarily by enhancing the removal of the
toxic proteins, although it possibly may also have additional
antiapoptotic effects (e.g. by eliminating toxic peptides
released by proteasomes as discussed below).
It is indeed unexpected that the activity of a cytosolic ami-
nopeptidase can regulate autophagic vacuole formation. PSA
inhibition was achieved using two unrelated small molecular
weight compounds: bestatin, a natural, slow binding, competi-
tive inhibitor of many aminopeptidases (35), and PAQ-22, a
synthetic, non-competitive inhibitor that does not act as a
substrate-mimic and binds to PSA at a distinct site (36–38).
Both compounds increased the formation of aggregates and
the toxicity of expanded huntingtin exon 1 at concentrations
that caused only a modest (50%) inhibition of its activity.
Thus, even minor variations in PSA activity, e.g. in human
polymorphisms, if they exist, have the potential of inﬂuencing
susceptibility to neurodegenerative disease.
PSA seems to be the major cytosolic aminopeptidase in cul-
tured cells as well as in brain, muscle and kidney (39). It
cleaves rapidly most N-terminal amino acids (especially
alanine) from peptides, and PSA accounts for approximately
80% of the total soluble aminopeptidase activity in human cer-
ebral cortex (40). Aminopeptidases such as PSA catalyse the
ﬁnal stages of the degradation of intracellular normal and
abnormal proteins releasing amino acids from peptides gener-
ated by the catabolism of proteins by the proteasome
(13,15,41). Thus, PSA potentially might link late steps in
protein degradation by the ubiquitin proteasome pathway to
functioning of the autophagic pathway. Certainly, regulation
of any cellular process by the activity of PSA or any amino-
peptidase represents an unusual mode of enzyme regulation
since amino acid removal would cause irreversible changes
in a protein. Alternatively, perhaps it may act to destroy a
regulatory peptide that somehow inhibits autophagy. It is note-
worthy that certain amino acids (especially leucine) activate
mTORC1 and thus inhibit macroautophagy (42). However,
the digestion by PSA of proteasome products would increase
the pool of free amino acids and thus should reduce autop-
hagy, while the exact opposite was observed. It remains poss-
ible that PSA could be involved in earlier stages in the
catabolism of some proteins; in fact, there is a general slow-
down in the degradation of proteins in bacteria lacking
multiple aminopeptidases (41), although such effects could
be indirect. For example, the in vivo half-life of a protein is
determined in part by the nature of its N-terminal
amino acid (termed the ‘N-end rule’). Thus, the removal of
the N-terminal amino acid from certain proteins by PSA
could expose destabilizing residues leading to their rapid
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bly, PSA might in this way alter the levels (or activity) of a
protein that is critical in the regulation of autophagy.
However, in most globular proteins, the N-terminal amino
acid is buried in the interior, so PSA would be expected to
act only on proteins with ‘loose ends’ and generally aminopep-
tidases preferentially attack shorter peptides.
A major challenge for future work will be to establish the
mechanism by which PSA promotes autophagy. The best
characterized physiological inhibitor of autophagy is mTOR.
However, we found no evidence for PSA inhibiting the
activity of mTOR (Supplementary Material, Fig. S5E and
F), and it seems quite unlikely that PSA promotes autophagy
simply by causing nutrient deprivation (since its overexpres-
sion does not impede growth). In fact, PSA had clear effects
on autophagic protein degradation in cells deprived of serum
and amino acids, where mTOR is markedly inhibited. Autop-
hagy is regulated by other mechanisms such as the phos-
phorylation of Bcl-2, which modulates autophagy via its
interaction with Beclin-1 (43). However, we did not observe
any effect of PSA on the levels of Bcl-2 phosphorylation (Sup-
plementary Material, Fig. S5E and F). Thus, we believe that
degradation or destabilization of an unknown inhibitory com-
ponent of autophagy remains the most likely explanation of
the activation of autophagy by PSA.
PSA can also act after the proteasome independently
of autophagy
While these studies focused on mutant huntingtin exon 1 and
other aggregation-prone proteins whose clearance seems to be
due to autophagy, it is noteworthy that PSA was also found to
prevent the formation of aggregates in cells expressing the WT
exon 1 protein and also with the WT full-length ataxin-3. In
other words, as suggested previously (15), this enzyme
appears to be an important defence against aggregate for-
mation due to non-expanded polyQ sequences as are found
in various normal proteins. Our previous data also indicate
that the clearance of WT huntingtin exon 1 does not depend
on autophagy and is mainly via the proteasome (30,44). The
proteasome would be predicted to continually produce short
polyglutamine tracts from this and other polyQ proteins,
since it cannot cleave between successive glutamine residues
in the polyQ stretch (6). Such isolated polyglutamine tracts
(even ones as short as 10Qs) are highly aggregate-prone if
not cleared from the cell. Because PSA is the only non-
lysosomal enzyme in tissue extracts that can degrade such
polyglutamine products (15), polyglutamine stretches should
accumulate and aggregate in cells when PSA is inhibited, as
was found here. In cells, the isolated polyglutamine tracts
not only aggregate but also sequester GFP or other tagged hun-
tingtin constructs with ﬂanking sequences (23,45). Because
PSA is an aminopeptidase that digests soluble polypeptides
one residue at a time and dissociates after each cleavage, it
should degrade these aggregation-prone polyglutamine
stretches only slowly. Thus, reducing its activity will have
important consequences on accumulation of shorter polygluta-
mine stretches, whereas the more aggregate-prone mutant pro-
teins (e.g. expanded polyQ proteins) tend to aggregate rapidly
due to their inherent tendency to misfold, and their clearance
by PSA appears to be more dependent on autophagy. In prin-
ciple, the aggregates seen with mutant huntingtin could arise
from seeds that are either the whole exon 1 fragment or the
proposed post-proteasome-isolated polyQ tract. Isolated
expanded polyQ tracts will seed and sequester GFP-tagged
exon 1 of mutant huntingtin. Since PSA regulates overall
aggregation mediated from exon 1 of huntingtin in an
autophagy-dependent manner, any contribution towards aggre-
gation of PSA acting as an aminopeptidase on isolated
expanded polyQ tracts derived from larger huntingtin frag-
ments will be very minor. Indeed, once huntingtin is engulfed
in an autophagosome, it will be inaccessible to the ubiquitin–
proteasome machinery and to PSA. Thus, our data show that
the predominant effect of PSA in these models of HD is via
autophagy.
Presumably, the physiological levels of PSA have evolved
so as to ensure the rapid elimination of peptides from the
nucleus and cytosol, but under the present experimental con-
ditions when an aggregation-prone protein is overexpressed,
PSA is not present in large excess over what is necessary to
clear the misfolded, toxic proteins or even the products of
WT huntingtin exon 1. Indeed, only a 50% reduction in PSA
activity using inhibitors in cell culture or the 50% reduction
in expression in PSA in tissues of heterozygous PSA+/2
mice led to greater content of aggregates formed by expanded
huntingtin exon 1. These observations and the protection by
overexpression argue that activation of autophagy by PSA is
a tightly regulated process, and that only a modest increase
in its activity might have beneﬁcial effects. Increasing PSA
activity thus represents a novel potential approach for
therapy of neurodegenerative diseases. It is noteworthy that
treatment of cells with PSA inhibitors for several days was
remarkably non-toxic. In contrast, proteasome or lysosomal
inhibitors are highly toxic when applied for more than 6–
12 h. While a low toxicity would thus be expected for
agents that would moderately increase the activity or
expression of PSA, a high level of PSA overexpression by
itself was toxic in Drosophila (data not shown). It is also note-
worthy that PSA expression is elevated in PC12 cells expres-
sing polyQ expanded exon 1 (22) and also in some neurons
expressing mutant tau (16). Thus, induction of PSA may
well represent an important cellular adaptation that reduces
the accumulation of toxic proteins and functions in host
defences against neurodegenerative disease (15).
MATERIALS AND METHODS
Details of plasmids used as well as cell culture methodology
and protocols for aggregate analysis, western blotting and
ﬁlter trap assays can be found in Supplementary information.
Inhibitors
PAQ-22 was from Wako, puromycin aminonucleoside was
from Biomol, PS-341 (Bortezomid or Velcade) was a gift
from Millenium. Bestatin, puromycin dihydrochloride, chloro-
quine, 3MA, NH4Cl and staurosporin were from Sigma. Fresh
stock solutions of chloroquine (50 mM) were prepared just
before experiments (ﬁnal concentration 50 mM). Fresh 3MA
Human Molecular Genetics, 2010, Vol. 19, No. 23 4583solutions (100 mM) were prepared in boiled PBS just before
experiments (ﬁnal concentration 10 mM).
Muscle electroporation
Adult CD1 male mice (25–35 g) were anaesthetized by intra-
peritoneal injection of Avertin (0.2 ml/10 g as 1.2% solution).
Fur overlying the hindlimb was removed, and the surgical site
was cleansed with betadine swab followed by isopropyl
alcohol wipe. Using sterile technique, a 0.5–1.0 cm longitudi-
nal incision was made in the skin overlying the tibialis anterior
muscle, and the underlying muscle was exposed by blunt dis-
section of the surrounding skin. A paddle electrode was then
introduced between the muscle and the underlying tibia.
Plasmid DNA in sterile saline (40 ml, 25 mg) was injected
into the muscle. A second paddle electrode was applied
gently over the muscle and electroporation performed (12 V,
20 ms duration, 5 pulses, 200 ms intervals) using an
ECM830 Electro Square Porator (BTX, Harvard Apparatus).
The electrodes were removed and the skin was closed by
suture. Post-operative analgesia was administered every 12 h
for the ﬁrst 24 h with buprenorphine 0.05 mg/kg SQ.
Additional analgesia was administered thereafter if there was
any evidence of continued animal discomfort. The animals
were followed for 1 week, after which time they are eutha-
nized by Halothane inhalation followed by cervical dislo-
cation, and the muscles harvested, quickly frozen in
liquid-nitrogen-cooled isopentane and stored at 2808C. Ten
micrometer muscle cryosections were analyzed for GFP/
mCherry ﬂuorescence after ﬁxation with 4% paraformalde-
hyde and Hoechst staining (10 mg/ml in PBS for 10 min)
using a Nikon 80i upright microscope in the Nikon Imaging
Center at Harvard Medical School. No gross evidence of
necrosis or inﬂammation as a result of the transfection pro-
cedure was noted. Inclusion size and number were analysed
with Metamorph using ﬁxed size and intensity thresholds.
Drosophila
Fly crosses and experiments were performed at 258C. All
crosses for individual experiments were performed at the
same time and under the same conditions.
For survival assays, virgins carrying either
P{UAS-dPsa}8.10 [PSA (47)] or UAS-RNAi constructs that
knockdown Psa [PSA-IR-R2 (referred to as PSA-RNAi1)
and PSA-IR-R3 (referred to as PSA-RNAi2), National Insti-
tute of Genetics Fly Stock Center, Japan] were crossed with
males expressing w; P{UAS-Q93httexon1}
4F1 [Q93 (24)] and
w; P{UAS-Q20httexon1} [Q20 (24)] in the nervous system
[using P{GawB}elav
C155, elav-Gal4 (46)]. Control ﬂies were
progeny of ﬂies expressing Q93 or Q20 under control of
elav-GAL4, crossed to w
1118 males that segregated from
some stocks of other UAS-RNAi lines and were therefore
representative of the genetic background of these lines. The
analysis was based on 100 female ﬂies per genotype divided
in groups of 10 ﬂies per vial. Flies were transferred to new
vials and counted every 2 days. Survival curves were plotted
using the Kaplan–Meier estimator. The statistical signiﬁcance
was calculated using the log-rank test (SPSS 11.0).
Pseudopupil analysis was performed at 4 days post-eclosion
as previously described (26). To evaluate the effect of PSA
overexpression, virgins of genotype y w; P{GMR-HD.
Q120}2.4 (GMR-Q120) or y w; P{GMR-HD.Q23} [GMR-
Q23 (25)] were crossed with males y w; P{gl-dPSA}A
[gl-PSA (16)]. As controls, the above ﬂies (GMR-Q120,
GMR-Q23 and gl-PSA) were crossed with w
1118 isogenic
males (48). To evaluate the effect of PSA downregulation
on neurodegeneration, virgins of genotype elav-GAL4
C155;
{GMR-HD.Q120}4.62/TM3 (elav-Gal4 GMR-Q120) or elav-
GAL4
C155; {GMR-HD.Q23} (elav-Gal4 GMR-Q23) were
crossed with the same UAS-RNAi or w
1118 control males as
described for the survival assay, and the progeny were
scored using the pseudopupil assay. Pictures were acquired
using an ×100 objective (Zeiss Axioscope2 microscope).
Comparisons were performed using paired t-tests using data
from ﬁve to seven independent experiments, each based on
approximately 10 individuals of each genotype, in which 15
ommatidia each were scored.
Protein degradation measurement
293A cells were seeded in six-well plates and transfected 24 h
later (conﬂuence 50%). Forty-eight hours after transfection,
fresh culture medium containing 5 mCi/ml L-[3,5-
3H]-tyrosine
(Perkin Elmer) was applied for 24 h to label long-lived pro-
teins. Cells were then washed twice for an hour with a chase
medium containing 2 mM tyrosine (in order to limit reincor-
poration of the
3H-tyrosine and to allow degradation of short-
lived proteins, total chase duration 2 h). Cells were then
washed with either culture medium (basal condition) or
HBSS (serum and amino acid starvation) containing 2 mm
tyrosine and the PSA, proteasome, lysosomes or autophagy
inhibitors for 1 h (pre-treatment before protein degradation
measurement). Cells were then washed with the same
medium and 200 ml of the medium was collected after 0, 1,
2, 3 and 4 h for quantitation of
3H-tyrosine release (protein
degradation measurement). Proteins were precipitated with
TCA (10% ﬁnal concentration) and pelleted. Radioactivity in
the TCA-soluble supernatant was measured using a 1900TR
liquid scintillation analyser (Packard). At the end of the
measurement period, cells were solubilized in 0.2 N NaOH
and an aliquot was taken to measure the residual radioactivity
in the cells. Total radioactivity is the sum of the residual radio-
activity in the cells and the TCA-soluble radioactivities at
different time points. Protein breakdown rates were expressed
as
3H-tyrosine released over time as a percentage of total
3H-tyrosine incorporated. Proteasomal, lysosomal and
autophagy-dependent proteolysis rates were determined pre-
cisely as done before by treating cells with 1 mM bortezo-
mib/velcade, 50 mM chloroquine or 10 mM 3MA, respectively.
PSA activity measurement
To prepare cytosolic extracts, 293A or MEF cells were washed
with ice-cold PBS twice and scraped in ice-cold lysis buffer
containing 50 mM phosphate buffer (pH 7.4), 0.5 mM CaCl2,
5m M MgCl2,1 m M DTT and 5% glycerol, collected in an
eppendorf and homogenized manually on ice. This homogen-
ate was spun at 10 000g for 15 min to remove the nuclear frac-
4584 Human Molecular Genetics, 2010, Vol. 19, No. 23tion and then at a higher speed of 100 000g for an hour to
remove membranous organelles. Protein concentration was
obtained using Coomassie Plus Protein Assay (ThermoFisher).
PSA activity was determined by monitoring for 5–20 min the
increase in ﬂuorescence (excitation 380 nm, emission 460 nm,
SpectraMax M5, Molecular Devices) caused by hydrolysis of
the substrate Ala-amc (Bachem, 100 mM ﬁnal) in 100 mlo f
lysis buffer containing 2–5 mg of protein from the cell
extract. Background from the ﬂuorescence of Ala-amc in the
absence of enzyme was subtracted.
To measure Ala-amc hydrolysis by intact cells, 293A cells
were plated in 96-well plate adapted for ﬂuorescence measure-
ment, grown in culture medium without phenol red containing
various concentrations of inhibitors for 24 h. Cells were
washed with fresh culture medium containing Ala-amc
100 mM and inhibitors and the increase in ﬂuorescence was
monitored for 1 h. Background from the ﬂuorescence of
medium containing Ala-amc in the absence of cells was sub-
tracted.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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